Department of Neurology, Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, AZ, United States of America.
Department of Radiology, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States of America.
Clin Imaging. 2021 Oct;78:296-300. doi: 10.1016/j.clinimag.2021.05.028. Epub 2021 Jun 1.
To determine whether brain atrophy was present in patients with anti-N-methyl-d-aspartate receptor encephalitis (anti-NMDARE) using qualitative and quantitative analyses of brain magnetic resonance imaging (MRI) and to explore clinical differences in patients with anti-NMDARE with or without brain atrophy.
A retrospective observational study encompassing the serologic, cerebrospinal fluid, and brain MRI data of 23 patients with anti-NMDARE was conducted. Median patient age was 14 years (interquartile range [IQR], 12 years). The cohort included 15 children (<18 years old) and 8 adults (≥18 years old). There were 6 male and 17 female patients. Imaging analysis involved 2 expert readers' observations of MRIs and automated volumetric quantification using NeuroQuant (CorTechs Labs, Inc.) software.
Of 23 pediatric and adult patients, 11 patients had 14 brain MRIs that were quantitatively analyzed. Quantitative NeuroQuant volumetric analysis showed atrophy in 9 of 14 MRIs for 7 of 11 patients compared to age-controlled normative data. In these 9 MRIs, atrophy was present in the temporal lobes (n = 9), cerebral cortex (n = 3), and cerebellum (n = 3). Qualitative analysis of 59 MRIs (23 patients) revealed volume loss in 6 patients: 5 with global cerebral and temporal lobe volume loss and 1 with temporal lobe volume loss. No patient showed cerebellar volume loss on qualitative analysis. Mean length of stay in the intensive care unit was not significantly different for patients with or without quantitative volume loss (3.5 [5.2] vs 27.4 [23.4] days; p = 0.08).
In this cohort of patients with anti-NMDARE, quantitative volumetric analysis showed brain atrophy, particularly affecting the temporal lobes, in 64% (7/11) of the patients. Qualitative analysis showed brain atrophy in 26% (6/23). These findings highlight the increased sensitivity of quantitative methods for volume loss detection. Larger studies are needed.
通过定性和定量分析脑磁共振成像(MRI),确定抗 N-甲基-D-天冬氨酸受体脑炎(抗 NMDARE)患者是否存在脑萎缩,并探讨伴有或不伴有脑萎缩的抗 NMDARE 患者的临床差异。
进行了一项回顾性观察研究,纳入了 23 例抗 NMDARE 患者的血清学、脑脊液和脑 MRI 数据。中位患者年龄为 14 岁(四分位距 [IQR],12 岁)。该队列包括 15 名儿童(<18 岁)和 8 名成人(≥18 岁)。其中 6 名男性和 17 名女性患者。影像学分析包括 2 位专家读者观察 MRI 和使用 NeuroQuant(CorTechs Labs,Inc.)软件进行自动容积定量。
在 23 例儿科和成人患者中,11 例患者的 14 份 MRI 进行了定量分析。定量 NeuroQuant 容积分析显示,与年龄匹配的正常数据相比,11 例患者中有 7 例的 14 份 MRI 中有 9 份存在萎缩。在这 9 份 MRI 中,7 例患者的颞叶(n=9)、大脑皮层(n=3)和小脑(n=3)存在萎缩。对 59 份 MRI(23 例患者)进行的定性分析显示,6 例患者存在体积损失:5 例存在全脑和颞叶体积损失,1 例存在颞叶体积损失。定性分析未见小脑体积损失。有或无定量体积损失的患者在重症监护病房的平均住院时间无显著差异(3.5[5.2]与 27.4[23.4]天;p=0.08)。
在本队列的抗 NMDARE 患者中,定量容积分析显示,11 例患者中有 64%(7/11)存在脑萎缩,尤其是颞叶。定性分析显示 26%(6/23)的患者存在脑萎缩。这些发现突出了定量方法在检测体积损失方面的更高敏感性。需要更大的研究。